In a recent study by Sugiyama et al., the tumor microenvironment (TME) of EGFR mutated LUADs showed increased Treg infiltration, and a combination treatment of anti PD-1 with EGFR tyrosine kinase inhibitor erlotinib showed better anti-tumor effects [53]. This evidence concerns the gene PDCD1 and neoplasm.